Michael J. Barber is a GE Officer and the VP of GE's healthymagination business strategy on global health. The healthymagination charter is (by 2015) to improve the quality of care by 15% or more, reduce the cost of procedures and processes through the appropriate use of GE technologies and services by 15% and increase access to technologies and services essential to health by 15%.
Prior to this position Barber, a 25+-year GE veteran, was Vice President and Chief Technology Officer for GE Healthcare, leading a technology team of more than 7,000 engineers, technologists and scientists working in diverse fields such as MRI, CT, ultrasound, patient monitoring, anesthesia, life sciences, imaging contrast agents and health-related R&D at GE Healthcare. Healthcare’s revenue totals over $17B and the company spends over $1B annually for R&D.
Barber started with GE in 1982 and has had a variety of roles in engineering, operations and product management. As the Manager of the Digital X-ray Detector Platform, Barber led a team that eliminated the need for film in X-ray procedures. Barber holds patents for novel X-ray system designs and has been directly involved with many product advances in the field of diagnostic imaging.
When Barber was selected to lead healthymagination in June 2009, GE Chairman and CEO Jeff Immelt remarked “Over the last four years, Mike has led all aspects of product development for advanced healthcare technologies. Mike knows how our technology can help patients. He knows what doctors, clinics and hospitals need to improve care and cut costs and he knows how to lead teams. With his deep experience in engineering and technology and his strong operations and process-driven expertise, Mike is the right leader to lead healthymagination and to grow our healthcare partnerships globally.”
Beth Comstock is Chief Marketing Officer and SVP of GE. She leads the company's organic growth and commercial innovation initiatives, and the sales, marketing and communications functions. She is responsible for the GE-wide business platforms ecomagination, devoted to reducing environmental impact with new technology, and healthymagination, focused on achieving sustainable health through innovation by lowering costs, improving quality and reaching more people.
She returned to the CMO role after having spent over two years as President of Integrated Media at NBC Universal. Beth oversaw the television ad sales, marketing and research teams, with a focus on new advertising innovations. She led the company’s digital media development and distribution, including the formation of hulu.com, Peacock Equity and the acquisition of ivillage.com.
In 2003, she was named GE's first Chief Marketing Officer in more than 20 years and as such, helped reinvigorate marketing across the company, introducing ecomagination, Imagination Breakthrough innovations and the "imagination at work" brand campaign.
Previously, Beth held a succession of publicity and promotions roles at GE, NBC, CBS and Turner Broadcasting. She began her career in local television production in Virginia.
Beth is a trustee of the Smithsonian's Cooper-Hewitt National Design Museum. She is a graduate of the College of William and Mary. She and her husband have two daughters.
Dr. Andrew C. von Eschenbach, M.D., was appointed Acting Commissioner of Food and Drugs in September 2005, where he immediately engaged an agenda to modernize the FDA. Under his leadership, many new programs were designed to strengthen the FDA in its mission to protect and promote public health. He emphasized FDA’s role in working with external partners to assure quality throughout the entire life cycle of the products it regulates while internally fostering, through process improvements, a regulatory pathway that is transparent and efficient while still rigorous and science led. Confirmed by the Senate as Commissioner in December 2006 and serving in the position until 2009, Dr. von Eschenbach emphasized innovation by fostering creative projects, including FDA’s Critical Path Initiative (designed to bring modern tools of science to the product development process); work plans like the FDA’s Food Protection Plan; and most especially the nurturing of the workforce through initiatives, such as an Agency-wide fellowship program and development of a new integrated campus for the Agency in White Oak, Maryland.
Dr. von Eschenbach joined FDA after serving for four years as Director of the National Cancer Institute (NCI) at the National Institutes of Health where he set an ambitious goal to eliminate the suffering and death due to cancer by rapid acceleration and integration of the discovery-development-delivery continuum. While at NCI, he committed resources to ensure the application to oncology of nanotechnology, genomics, proteomics, bioinformatics, and other emerging technologies. At the time of his appointment by President Bush to serve as Director of NCI, he was President-Elect of the American Cancer Society. Dr. von Eschenbach entered government service after an outstanding career over three decades as a physician, surgeon, oncologist and executive that included numerous leadership roles from Chairman of the Department of Urologic Oncology to Executive Vice President and Chief Academic at the University of Texas M.D. Anderson Cancer Center in Houston, an institution world renowned for the magnitude and excellence of its clinical and research cancer programs. An internationally renowned cancer specialist and author of more than 200 scientific articles and studies, Dr. von Eschenbach has served in numerous leadership roles, including serving as one of the founding members of the National Dialogue on Cancer. He has received numerous professional awards and honors. In 2006, Dr. von Eschenbach was named one of Time magazine’s “100 most influential people to shape the world,” and in both 2007 and 2008, he was selected as one of the Modern Healthcare/Modern Physician’s “50 Most Powerful Physician Executives in Healthcare.”
Dr. von Eschenbach earned a B.S. from St. Joseph’s University in his native Philadelphia and his medical degree from Georgetown University School of Medicine in Washington, D.C. He served as a Lt. Commander in the U.S. Navy Medical Corps. After completing a residency in urologic surgery at Pennsylvania Hospital in Philadelphia, he was an instructor in urology at the University of Pennsylvania School of Medicine. He completed a Fellowship in Urologic Oncology at the University of Texas M.D. Anderson Cancer Center.
He has been married to his childhood sweetheart, Madelyn, for over 40 years, and they are proud parents of four children and elated grandparents of six.
Michael J. “Mike” Harsh is Vice President and Chief Technology Officer for GE Healthcare, a $17 billion division of General Electric that helps its customers to deliver better care to more people around the world at a lower cost. GE Healthcare consists of diverse businesses including medical imaging and information technologies, medical diagnostics, patient monitoring systems, technologies facilitating drug discovery, biopharmaceutical manufacturing technologies, and performance improvement and performance solutions services.
Mike leads the global Science and Technology Organization for GE Healthcare, focusing its research and development teams on creating and sustaining innovative diagnostics, healthcare IT, and life sciences product offerings that reduce healthcare costs, improve healthcare quality, and increase patient access to healthcare globally.
Mike began his career at GE in 1979 as an electrical design engineer in nuclear imaging, and subsequently held numerous design and engineering management positions with X-ray, Ultrasound, Magnetic Resonance Imaging (MRI), Patient Monitoring, and Information Technologies.
Subsequently, Mike was named Global Technology Leader - Imaging Technologies Lab at the GE Global Research Center, where he led the research for imaging technologies across the company as well as the research associated with computer visualization/image analysis and superconducting systems. Mike was named an officer of the General Electric Company in November 2006.
Mike received a bachelor’s degree in Electrical Engineering from Marquette University, Milwaukee, Wisconsin, and he holds numerous U.S. patents in the field of medical imaging and instrumentation.
Mark M. Little was named senior vice president and director of GE Global Research in October 2005, becoming only the ninth director in the organization's 105 year history. In that role Mr. Little is responsible for leading one of the world's largest and most diversified industrial research and technology organizations.
At Global Research, approximately 2,600 people from virtually every major scientific and engineering discipline focus on the company's long-range technology needs. The organization has research facilities in the United States, India, China and Germany, working in collaboration with GE businesses around the world.
Prior to his current role, Mr. Little was vice president of GE Energy's power-generation segment headquartered in Schenectady, New York. GE Energy is a world-leading supplier of power generation equipment including gas, steam, wind and hydro-turbine generators, turnkey power plant services, gasification technologies and integrated gasification combined cycle.
Mr. Little joined GE in 1978, starting out in the company's Turbine business. After holding several management positions in engineering, he was named product general manager for generators in 1989. In 1991 he became general manager of business development for GE Energy, responsible for strategic planning and joint venture development. In 1992 he was appointed product general manager for gas turbines and in 1994 he was named vice president of Power Generation Engineering. He assumed responsibility for the large turbine generator segments of power generation in 1997, and in 2004 he was appointed to lead the combined thermal, wind and hydro power generation group.
Mr. Little holds bachelor's and master's degrees in mechanical engineering from Tufts and Northeastern universities respectively, and he earned a Ph.D. in mechanical engineering from Rensselaer Polytechnic Institute.
Dr. Newman is a surgical oncologist, Associate Professor of Surgery and Director of the Breast Care Center for the University of Michigan in Ann Arbor, Michigan. Dr. Newman holds a Masters Degree in Public Health from Harvard University, and she also obtained her undergraduate education at Harvard University with a major in chemistry. She attended medical school and completed her general surgery residency training at the State University of New York Health Science Center at Brooklyn. Dr. Newman was recruited to remain at Downstate following completion of her postgraduate training, and served as an Assistant Professor of Surgery with this program for several years. She completed her fellowship in surgical oncology at the M.D. Anderson Cancer Center. She is board-certified in General Surgery and holds an American Board of Surgery Added Qualifications Certificate in Surgical Critical Care. Prior to assuming her current position at the University of Michigan, Dr. Newman served as Assistant Professor of Surgery at the M.D. Anderson Cancer Center in Houston, Texas with a full-time commitment to research and clinical practice in the Surgical Breast Section, and was Associate Director for the Walt Breast Center at Wayne State University for two years.
Dr. Newman's primary research has focused on ethnicity-related variation in breast cancer risk and outcome, the evaluation and management of high-risk patients (including ductal lavage); broadened applications for induction chemotherapy, and special surgical techniques such as the skin-sparing mastectomy and lymphatic mapping/sentinel lymph node biopsy. Her basic science research has involved investigations of p27 and Her2/neu in breast cancer, and her extensive work has been published in numerous peer-reviewed medical journals. She maintains a very active community service record, and currently serves as Chief National Medical Advisor for the Sisters Network, Inc., a national African American breast cancer survivors support organization.
Active society memberships include: American College of Surgeons; Society of Surgical Oncology; the Inter-cultural Cancer Council, American Society of Clinical Oncology; American Society of Breast Disease, for which she is a Board Member; American Society of Breast Surgeons; and the American Association of Clinical Research. Dr. Newman also serves on the Executive Council and chairs the Special Populations Committee of the American College of Surgeons Oncology Group, and she serves as Board member for the Great Lakes Division of the American Cancer Society. She is a member of the Editorial Boards for Annals of Surgical Oncology and The Breast Journal.
Tim O'Reilly is the founder and CEO of O'Reilly Media, Inc., thought by many to be the best computer book publisher in the world. Over the years, Tim has built a culture where sustainable innovation is a key tenet of business philosophy. His active engagement with technology communities both drives the company's product development and informs its marketing.
Tim is on the board of Safari Books Online and is a partner in O'Reilly AlphaTech Ventures. Tim graduated from Harvard College in 1975 with a B.A. cum laude in classics. His honors thesis explored the tension between mysticism and logic in Plato's dialogues. Any discussion of Tim is incomplete without a fuller understanding of the company he founded. O'Reilly Media spreads the knowledge of innovators through its books, online services, magazines, research, and conferences. Since 1978, O'Reilly has been a chronicler and catalyst of leading-edge development, honing in on the technology trends that really matter and galvanizing their adoption by amplifying "faint signals" from the alpha geeks who are creating the future. An active participant in the technology community, the company has a long history of advocacy, meme-making, and evangelism.
Publisher of the iconic "animal books" for software developers, creator of the first commercial website (GNN), organizer of the summit meeting that gave the open source software movement its name, leader in Gov 2.0 "government as a platform" efforts, and prime instigator of the DIY revolution through its MAKE magazine and Craftzine.com, O'Reilly Media continually concocts new ways to connect people with the information they need.
Sue Siegel General Partner, Mohr Davidowwww.website.comMenlo Park, California
Susan Siegel is a general partner at Mohr Davidow Ventures.
Siegel joined the firm in 2007 after a distinguished career as a corporate leader and with a background in biochemistry and molecular biology. She partners with entrepreneurs and companies that offer solutions to pressing healthcare challenges like age-onset conditions, lifestyle-induced health trends and consumer-driven wellness preservation, as well as firms improving healthcare economics.
She has over 25 years experience commercializing key enabling technologies in biomedical research and healthcare. Siegel was the president and director of Affymetrix Inc., which she joined in 1998 to lead the commercialization efforts for the company’s state-of-the-art GeneChip technology.
From April 1998 to August 1999, she served as its senior vice president, marketing and sales. After this, Ms. Siegel took the helm as president and shortly after was appointed to the board. She led the company through a tremendous growth phase. During Siegel’s presidency, the company scaled to almost $400 million in yearly revenue and was valued as a multi-billion market cap growth company.
Sue received a M.S. in Biochemistry and Molecular Biology from Boston University Medical School where she studied cellular differentiation in mouse embryonic carcinoma stem cells. She received her B.S. in Biology from the University of Puerto Rico.
Risa Stack Partner, Kleiner Perkins Caufield & Byerswww.website.comSan Francisco, California
Dr. Risa Stack has 15 years of experience investing in personalized medicine, therapeutics, and platform technologies. Her investment career spans incubations to public companies. Most recently she has focused on starting companies, often taking operational roles.
Since joining Kleiner Perkins Caufield & Byers in 2003, Risa has worked to build and support KPCB's personalized medicine portfolio. She has been the founding CEO and a board member of several personalized medicine companies including Nodality and CardioDx. Risa is a board observer at Xdx, Veracyte, and Tethys. In addition to her work directly with portfolio, Risa is involved in developing public policy in molecular diagnostics and personalized medicine.
Risa is involved in the development of therapeutics companies including Trius and Corthera. She was most recently a board member of Corthera which was sold to Novartis in December 2009. She is also a board observer at Epizyme and Pacific Biosciences.
Prior to joining KPCB, Risa was a Principal at J.P. Morgan Partners in the life science practice for six years. While at J.P. Morgan Partners she sponsored a series of investments including Acurian, Connetics (acquired by Steifel Laboratories), Diatide (acquired by Berlex), Ilex Oncology (acquired by Genzyme), Illumina, and Triangle Pharmaceuticals (acquired by Gilead). Risa was also involved in JP Morgan Partners' international investing efforts, which included European life sciences companies and managing a portfolio of Israeli early stage life science and IT companies.
Before joining the venture capital industry, Risa worked as a Derivative Specialist on the Chicago Board of Trade where she traded futures and options on government securities.
Risa received her B.S. in Genetics and Development with distinction from the University of Illinois and her Ph.D. in Immunology from the University of Chicago. She was also a member of the second class of Kauffman Fellows.
Risa is a member of the advisory board of the National Summit on Personalized Healthcare and GE's Healthymagination effort.
Risa was named as one of the 100 Most Influential Women in Business by the San Francisco Business Times in 2004.
Professor Justin Stebbing trained in medicine at Trinity College Oxford, where he gained a triple first class degree. After completion of junior doctor posts in Oxford, he undertook a training and a residency at The Johns Hopkins Hospital in the US, returning to London to continue his career in oncology at The Royal Marsden and St Bartholomew's Hospitals. Professor Stebbing’s PhD research investigated the interplay between the immune system and cancer.
Professor Stebbing has published over 400 peer-reviewed papers in journals such as the Lancet, New England Journal, Blood, the Journal of Clinical Oncology, Annals of Internal Medicine, as well as writing for national newspapers and presenting new data on optimal cancer therapies at major international conferences. His focus at Imperial is on new therapies in cancer, and the systemic management of patients with solid malignancies. His laboratory work is concentrated on new druggable target discovery.
He is a Fellow of the Royal College of Physicians, the American Board of Internal Medicine and the Royal College of Pathologists, and sits on the advisory Boards of a number of international cancer committees. He chairs the World Vaccine Congress and is on the editorial board of a number of world leading general medical and cancer journals such as the Journal of Clinical Oncology. In 2011, work Justin's team published in Nature Medicine outlines the discovery of a new cancer-causing gene.
Rafael A. Torres is Managing Director and Healthymagination Fund leader for GE Equity, GE Capital’s private equity investment arm, and GE’s center of excellence for private equity and venture capital. Rafael is responsible for equity strategy and investments in the healthcare sector as well as for GE Equity’s healthcare portfolio.
Rafael has led the healthcare team at GE Equity in investments in multiple segments of the healthcare industry, including healthcare services, medical devices, healthcare IT and life sciences in the US, Europe, Middle East and Asia. He currently serves on the board of InSightec and is an observer on the boards of CardioDx and Navinet.
Before joining GE Capital, Rafael was Global Director of Business Development for Pharmaceutical Enterprises at GE Healthcare. While in this role he led strategic investments in medical device and pharmaceutical companies. Prior to this role, Rafael was Integration Programs Leader for GE Healthcare’s $10B acquisition of Amersham plc, based in London, UK, where he was responsible for securing acquisition synergies and develop strategy for GE Healthcare. Rafael joined GE Healthcare in 2001 as Global Business Development Manager where he covered medical devices , healthcare IT and life sciences.
Prior to joining GE, Rafael held various positions at The Boston Consulting Group, AT Investments and Citibank. Rafael received a BA in Economics from Universidad del Pacifico, Lima, Peru and an MBA from Harvard Business School where he was an OAS scholar.
Pascale Witz is the President and Chief Executive Officer of GE Healthcare’s Medical Diagnostics business (MDx), and an officer of the General Electric Company.
MDx is a $2B global leader in diagnostic imaging agents, with nearly 5,000 employees dedicated to creating, manufacturing and marketing high-quality contrast media and molecular imaging agents, including Visipaque™, Omnipaque™, Omniscan™, Myoview™, AdreView™, DaTSCAN™, and Hexvix™.
Pascale joined GE Healthcare in 1996, and has served successfully in a number of senior management roles, including leading the Functional Imaging (Nuclear Medicine and PET) business in EMEA, and the CT (Computed Tomography) business in EMEA. Prior to her current role, she was in charge of the global Interventional business, a $700M business unit that develops innovative medical technologies for interventional radiology and cardiology.
Prior to joining GE, Pascale worked in a molecular biology research laboratory, and spent five years in the pharmaceutical industry.
Pascale has been an active leader in the GE Women's Network for some years and now serves on the executive board. The GE Women's Network boasts a membership of over 180,000 women globally with a goal of focusing on the professional development of women throughout the company.
Pascale holds a Masters degree in life sciences/molecular biology from INSA Lyon, and an MBA from INSEAD.